Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 11/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2135656 | 0.99 | HTR7 (0.64) | HTR7ATMMEN1KMT2AHTR6 | |
| SCHEMBL8979909 | 0.97 | HTR7 (0.65) | HTR7ATMMEN1KMT2AHTR6 | |
| Hydrochloric Acid SCHEMBL4232155 | 0.96 | HTR7 (0.64) | HTR7ATMMEN1KMT2AHTR6 | |
| SCHEMBL8980041 | 0.96 | HTR7 (0.64) | HTR7ATMMEN1KMT2AHTR6 | |
| Hydrochloric Acid SCHEMBL4233165 | 0.95 | HTR7 (0.63) | HTR7ATMMEN1KMT2AHTR6 | |
| SCHEMBL10035540 | 0.87 | HTR7 (0.67) | HTR7ATMMEN1KMT2AHTR6 | |
| Hydrochloric Acid SCHEMBL2137542 | 0.86 | HTR7 (0.66) | HTR7ATMMEN1KMT2AHTR6 | |
| SCHEMBL10035519 | 0.85 | HTR7 (0.62) | HTR7HTR6 | |
| SCHEMBL10035565 | 0.85 | HTR7 (0.69) | HTR7HTR6 | |
| SCHEMBL8983206 | 0.85 | HTR7 (0.61) | HTR7ATMMEN1KMT2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-7211584-B2 | 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-01 | — | — | US | disclosed |
| US-7211584-B2 | 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088450-A1 | 5-ht7 receptor antagonists | HTR7, HTR1A, HTR5A | HTR7 1/4885ATM 2056/4885MEN1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.